Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical validation of CYP2B6-guided efavirenz dosing in adults with HIV infection
PACTR202105618971235Phase 2Completed
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efavirenz in human immunodeficiency virus infection (HIV). Primary endpoints: Viral load and Neuropsychiatric adverse drug reactions. Started Apr 2018; status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202105618971235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202105618971235.